JPH01156956A - プロスタグランジン誘導体エステル - Google Patents
プロスタグランジン誘導体エステルInfo
- Publication number
- JPH01156956A JPH01156956A JP63248747A JP24874788A JPH01156956A JP H01156956 A JPH01156956 A JP H01156956A JP 63248747 A JP63248747 A JP 63248747A JP 24874788 A JP24874788 A JP 24874788A JP H01156956 A JPH01156956 A JP H01156956A
- Authority
- JP
- Japan
- Prior art keywords
- prostaglandin
- ischemia
- group
- polymer
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003180 prostaglandins Chemical class 0.000 title claims description 34
- 150000002148 esters Chemical class 0.000 title claims description 22
- 208000028867 ischemia Diseases 0.000 claims abstract description 34
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims abstract description 24
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 23
- 229920000642 polymer Polymers 0.000 claims abstract description 20
- 230000002378 acidificating effect Effects 0.000 claims abstract description 13
- 208000014674 injury Diseases 0.000 claims abstract description 13
- 210000000056 organ Anatomy 0.000 claims abstract description 12
- 201000004792 malaria Diseases 0.000 claims abstract description 11
- BGKHCLZFGPIKKU-UHFFFAOYSA-N (13E,15S)-15-hydroxy-9-oxo-prosta-10,13-dienoic acid Natural products CCCCCC(O)C=CC1C=CC(=O)C1CCCCCCC(O)=O BGKHCLZFGPIKKU-UHFFFAOYSA-N 0.000 claims abstract description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 9
- MYHXHCUNDDAEOZ-UHFFFAOYSA-N Prostaglandin A&2% Natural products CCCCCC(O)C=CC1C=CC(=O)C1CC=CCCCC(O)=O MYHXHCUNDDAEOZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 210000002569 neuron Anatomy 0.000 claims abstract description 8
- BGKHCLZFGPIKKU-LDDQNKHRSA-N prostaglandin A1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1CCCCCCC(O)=O BGKHCLZFGPIKKU-LDDQNKHRSA-N 0.000 claims abstract description 8
- 206010021143 Hypoxia Diseases 0.000 claims abstract description 7
- YBHMPNRDOVPQIN-UHFFFAOYSA-N (13E,15S)-15-Hydroxy-9-oxo-8(12),13-prostadienoic acid Natural products CCCCCC(O)C=CC1=C(CCCCCCC(O)=O)C(=O)CC1 YBHMPNRDOVPQIN-UHFFFAOYSA-N 0.000 claims abstract description 6
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960000711 alprostadil Drugs 0.000 claims abstract description 6
- PRFXRIUZNKLRHM-UHFFFAOYSA-N l-prostaglandin B2 Natural products CCCCCC(O)C=CC1=C(CC=CCCCC(O)=O)C(=O)CC1 PRFXRIUZNKLRHM-UHFFFAOYSA-N 0.000 claims abstract description 6
- YBHMPNRDOVPQIN-VSOYFRJCSA-N prostaglandin B1 Chemical compound CCCCC[C@H](O)\C=C\C1=C(CCCCCCC(O)=O)C(=O)CC1 YBHMPNRDOVPQIN-VSOYFRJCSA-N 0.000 claims abstract description 6
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims description 12
- 230000001681 protective effect Effects 0.000 claims description 12
- 230000005779 cell damage Effects 0.000 claims description 11
- 208000037887 cell injury Diseases 0.000 claims description 11
- 230000008733 trauma Effects 0.000 claims description 11
- 208000007502 anemia Diseases 0.000 claims description 9
- 210000000278 spinal cord Anatomy 0.000 claims description 7
- 125000005079 alkoxycarbonylmethyl group Chemical group 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 13
- 230000006378 damage Effects 0.000 abstract description 12
- 208000027418 Wounds and injury Diseases 0.000 abstract description 6
- 206010019663 Hepatic failure Diseases 0.000 abstract description 3
- 230000000747 cardiac effect Effects 0.000 abstract description 3
- 210000000170 cell membrane Anatomy 0.000 abstract description 3
- 230000002633 protecting effect Effects 0.000 abstract description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract description 2
- 208000033626 Renal failure acute Diseases 0.000 abstract description 2
- 208000006011 Stroke Diseases 0.000 abstract description 2
- 239000003513 alkali Substances 0.000 abstract description 2
- -1 alkoxycarbonylmethyl ester Chemical class 0.000 abstract description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 abstract 3
- 206010002660 Anoxia Diseases 0.000 abstract 1
- 241000976983 Anoxia Species 0.000 abstract 1
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 abstract 1
- 230000007953 anoxia Effects 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 125000000468 ketone group Chemical group 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 230000010412 perfusion Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 206010008118 cerebral infarction Diseases 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 210000004413 cardiac myocyte Anatomy 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000000302 ischemic effect Effects 0.000 description 6
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 125000004185 ester group Chemical group 0.000 description 4
- 230000007574 infarction Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 230000007087 memory ability Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- NHYXMAKLBXBVEO-UHFFFAOYSA-N bromomethyl acetate Chemical compound CC(=O)OCBr NHYXMAKLBXBVEO-UHFFFAOYSA-N 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- RGHQKFQZGLKBCF-UHFFFAOYSA-N 2-bromoethyl acetate Chemical compound CC(=O)OCCBr RGHQKFQZGLKBCF-UHFFFAOYSA-N 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 101100102624 Drosophila melanogaster Vinc gene Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 241000031165 Pseudopannota vinckei Species 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- SWLQAGBBUFCESY-UHFFFAOYSA-N ethyl-di(propan-2-yl)azanium;bromide Chemical compound Br.CCN(C(C)C)C(C)C SWLQAGBBUFCESY-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10471387A | 1987-10-02 | 1987-10-02 | |
| US07/104,713 | 1987-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH01156956A true JPH01156956A (ja) | 1989-06-20 |
Family
ID=22301970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63248747A Pending JPH01156956A (ja) | 1987-10-02 | 1988-10-01 | プロスタグランジン誘導体エステル |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPH01156956A (enrdf_load_html_response) |
| IN (1) | IN167720B (enrdf_load_html_response) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5113757A (ja) * | 1974-07-02 | 1976-02-03 | Sankyo Co | Purosutaguranjinjudotaino seiho |
| JPS51131859A (en) * | 1975-04-18 | 1976-11-16 | Schering Ag | Optically active and ceramic 111oxooprostaglandin derivatives* process for manufacture thereof and prostaglandinnworking agents containing said compounds |
| JPS5536470A (en) * | 1978-07-08 | 1980-03-14 | Hoechst Ag | Novel prostaglandin derivative of delta 2*44111deoxyypge series |
| JPS5879973A (ja) * | 1981-11-09 | 1983-05-13 | Ono Pharmaceut Co Ltd | プロスタグランジン誘導体の重合体、その製造方法及び該重合体を有効成分として含有する治療剤 |
-
1988
- 1988-09-30 IN IN682/MAS/88A patent/IN167720B/en unknown
- 1988-10-01 JP JP63248747A patent/JPH01156956A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5113757A (ja) * | 1974-07-02 | 1976-02-03 | Sankyo Co | Purosutaguranjinjudotaino seiho |
| JPS51131859A (en) * | 1975-04-18 | 1976-11-16 | Schering Ag | Optically active and ceramic 111oxooprostaglandin derivatives* process for manufacture thereof and prostaglandinnworking agents containing said compounds |
| JPS5536470A (en) * | 1978-07-08 | 1980-03-14 | Hoechst Ag | Novel prostaglandin derivative of delta 2*44111deoxyypge series |
| JPS5879973A (ja) * | 1981-11-09 | 1983-05-13 | Ono Pharmaceut Co Ltd | プロスタグランジン誘導体の重合体、その製造方法及び該重合体を有効成分として含有する治療剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| IN167720B (enrdf_load_html_response) | 1990-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW580392B (en) | Process for preparing synthetic soil-extract materials and medicaments based thereon | |
| Vane | Prostaglandins and the aspirin-like drugs | |
| JP2002510336A (ja) | 水溶性ケトプロフェン塩を含有する薬学的調製物及びその使用方法 | |
| BR112020019192A2 (pt) | Composição farmacêutica que compreende ácido deoxicólico | |
| JP2003509366A (ja) | γ−ヒドロキシブチレートを含むポリマーおよびオリゴマーの治療的用途 | |
| JPS5823630A (ja) | 薬剤禁断症状の処置剤 | |
| SU1002356A1 (ru) | Способ получени иммобилизованного фибринолизина | |
| PT2087890E (pt) | Preparação de libertação sustentada para terapêuticas de regeneração de tecidos | |
| US9265837B1 (en) | 5α-androstane-3β,5,6β-triol injection and preparation method therefor | |
| JP2018508479A (ja) | 虚血性脳卒中を予防・治療するための薬物の調製におけるビフェノールの使用 | |
| JPH04149126A (ja) | 経粘膜投与用医薬組成物 | |
| CN113150065A (zh) | 一种合成肽及其应用 | |
| CN116672325B (zh) | 一种包覆中性粒细胞膜的聚芬戈莫德纳米前药的制备方法 | |
| JP2018503637A (ja) | ビフェニル誘導体及びその使用 | |
| WO2013177927A1 (zh) | 注射用埃索美拉唑钠冻干粉组合物及其制备方法 | |
| WO2021198216A1 (en) | New method to treat the hepatotoxicity induced by amanitins | |
| JPH01156956A (ja) | プロスタグランジン誘導体エステル | |
| CN111278452B (zh) | 以阿林肽为活性成分的尿毒症药物 | |
| RU2131246C1 (ru) | Агент, ускоряющий разрастание эндотелиальных клеток | |
| US4840968A (en) | Preparation and uses of new prostaglandin derivatives which protect cell membranes against ischemic, physical, chemical, and biological injuries | |
| RU2189813C1 (ru) | Лекарственное средство антигипоксического действия | |
| CN116999541A (zh) | 一种具有明胶酶抑制作用的抗氧化功能纳米酶及其制备方法和应用 | |
| RU2153329C2 (ru) | Антигельминтное средство | |
| JPH02193931A (ja) | 角膜疾患治療用点眼剤 | |
| RU2217158C1 (ru) | Способ профилактики и лечения язв желудка у животных |